for the PACTG 219C Study Team and the Pediatric HIV/AIDS Cohort Study (PHACS) Objective: To estimate the association of age of viral suppression and central nervous system penetration effectiveness (CPE) score with neurocognitive functioning among school-age children with perinatally acquired HIV infection (PHIVþ).
Introduction
Children and adolescents with perinatally acquired HIV infection (PHIVþ) are vulnerable to subtle-to-severe neurocognitive problems during development. Introduction of combination antiretroviral therapy (cART) has resulted in a dramatic decrease in incidence of severe neurocognitive impairments; however, HIV-infected children on suppressive cART regimens may still experience neurocognitive deficits [1] [2] [3] [4] . HIV-associated neurocognitive disorders are thought to be due to virusspecific effects via direct infection of brain macrophages and microglia, and indirectly via virus-induced immune activation and inflammatory responses [5] [6] [7] . cART improves immunologic status and produces viral suppression in the peripheral blood; however, it remains unclear what impact cART has on the development of HIVassociated neurocognitive disorders in children as they age through adolescence and young adulthood [8] .
Recent data have shown that initiation of cART early in infancy results in significantly better neurodevelopmental scores at 1 year of age [9] . Initiating cART during the preschool years (<6 years) also appears to positively affect neurodevelopment, as PHIVþ children ages 18-71 months with lower neurodevelopmental function relative to their HIV-exposed uninfected peers demonstrated developmental gains after 1 year of cART [10] . In contrast, children who initiated early cART (i.e. without clinical and/or immunological progression) later in childhood (median age 6.4 years) did not experience greater cognitive improvement compared with children who initiated cARTwhen such progression had occurred, highlighting the importance of early cART initiation in infancy [11] . Despite the recent evidence for the benefit of early cART on neurodevelopment in early childhood, it remains unclear whether this positive effect will persist through school-age years and adolescence. Antiretroviral medications penetrate the central nervous system (CNS) to differing extents. Despite viralsuppressing levels in the blood, there may be low drug concentrations in the CNS, potentially allowing for replication of the virus in that system. Studies in adults on the effect of the central nervous system penetration effectiveness (CPE) score [12, 13] of a patient's cART regimen on neurocognitive outcomes have been conflicting [14] [15] [16] [17] [18] [19] [20] [21] , and pediatric data have been limited [22, 23] . Our study aimed to clarify this question by directly evaluating the impact of CPE score on neurocognitive outcomes.
As we move toward diagnosis and initiation of cART in infancy, it is important to determine whether early initiation of effective therapy benefits neurocognitive functioning beyond the immediate early childhood period. The main purpose of our study was to determine the effect of age at viral suppression on school-age neurocognitive outcomes. As a secondary objective, we investigated the association between CPE score and school-age neurocognitive functioning.
Methods

Study population
Study participants were from two US-based multisite prospective cohort studies, the Adolescent Master Protocol (AMP) of the Pediatric HIV/AIDS Cohort Study (PHACS) network and the Pediatric AIDS Clinical Trials Group (PACTG) 219C cohort. Both studies enrolled children, whether infected or uninfected, who were born to an HIV-infected mother. The PHACS AMP study enrolled children ages 7 to <16 years from 15 sites from March 2007 through November 2009, to evaluate the impact of HIV infection and antiretroviral therapy (ART) on preadolescents and adolescents with perinatal HIV infection. Eligibility criteria for PHACS AMP included complete documentation of ART history either from medical records or from participation in other cohort studies. Follow-up is ongoing. PACTG 219C enrolled individuals from 89 sites who were younger than 21 years of age from January 2000 through May 2007, to study the long-term effects of ART and HIV disease progression. Many of the children enrolled in AMP had previously participated in PACTG 219C. Only perinatally HIV-infected children were included in the present analysis. Eligible participants for this analysis were also required to complete a neurocognitive assessment at 6 years of age or older and have at least two viral load measurements with one of the measurements either prior to or within 6 months after ART initiation. Viral load measurements performed prior to entry into either PHACS AMP or PACTG 219C were retrospectively obtained through medical chart abstraction as dictated by the original study protocol.
Institutional review boards at participating sites and the Harvard School of Public Health approved both studies. Parents or legal guardians provided written informed consent for minor youth, and youth provided assent per local institutional review board guidelines or consent if older than 18 years.
Cognitive outcome measures
Neurocognitive functioning was measured using the Wechsler Intelligence Scale for Children, Third or Fourth Edition (WISC-III or WISC-IV) [24] [25] [26] . All children in AMP were assessed using the WISC-IV; children in 219C were assessed using either the WISC-III or the WISC-IV, following the revision of the WISC-III in 2003. If a child completed multiple tests, the earliest valid test results were used in these analyses. Both the WISC-III and WISC-IV provide a Full-Scale Intelligence Quotient (FSIQ) to represent overall cognitive ability. In addition, verbal comprehension [Verbal IQ (VIQ) for WISC-III and Verbal Comprehension Index (VCI) for WISC-IV] and perceptual reasoning [Performance IQ (PIQ) for WISC-III and Perceptual Reasoning Index (PRI) for WISC-IV] are evaluated using combinations of subtests of the WISC-III and WISC-IV, yielding composite scores for each domain. The corrected correlation coefficients of composites for the WISC-III and WISC-IV indicate that the WISC-III and WISC-IV measure similar constructs, with coefficients of 0.74 (WISC-III PIQ/ WISC-IV PRI), 0.87 (WISC-III VIQ/WISC-IV VCI), and 0.89 (WISC-III FSIQ/WISC-IV FSIQ) [26] . The primary outcome of the analysis was FSIQ; PIQ/PRI and VIQ/VCI were also examined as secondary outcomes. Validity of test results was reviewed by neuropsychologists and all test scores determined to be invalid were excluded from the analyses.
Exposure measures
Earliest age at viral suppression Five age cutoffs, at 1, 2, 3, 4, and 5 years old, were used to classify viral suppression status. Viral suppression was considered achieved when two consecutive HIV-1 RNA viral load measures 400 copies/ml or less were obtained 1-6 months apart, with at least the first measurement obtained prior to the age cutoff (e.g. an infant who achieved viral suppression at 8 months of age but whose consecutive suppression was not obtained until after 1 year of age would be considered virally suppressed before age 1).
Central nervous system penetration effectiveness score of initial antiretroviral therapy regimen The initial ART regimen was defined as the first regimen received before age 5 with duration more than 2 weeks. The CPE score of a specific ART regimen was calculated as the sum of the individual CPE scores of each drug within the regimen. The CPE score for each antiretroviral drug was obtained using a previously validated ranking system that assigns a score of 1-4 to each antiretroviral (1 ¼ lowest CNS penetration; 4 ¼ highest CNS penetration) [12] .
Weighted-average central nervous system penetration effectiveness score by each age cutoff To calculate the weighted-average CPE score at each age cutoff, the CPE score of each regimen was first multiplied by the duration of the regimen, and then the sum of all CPE scores was divided by the duration of each time period of interest.
Demographic and clinical covariates
The following child and caregiver sociodemographic variables were evaluated as potential confounders of the associations between the exposure and outcome measures: child age, sex, race, ethnicity, primary language (English versus other), low birth weight (<2500 g), birth cohort (1984-1995 versus 1996-2002) , primary caregiver type (biological parent versus other), and caregiver education level (less than high school versus higher). Clinical information, including child's pretreatment nadir CD4% and peak viral load, Center for Disease Control and Prevention (CDC) disease classification, diagnosis of HIV-related encephalopathy, exposure to antiretrovirals for the prevention of mother-to-child transmission (PMTCT), and version of Wechsler assessment (WISC-III or WISC-IV), were also evaluated.
Statistical analyses
Summary statistics for background characteristics, exposures, and outcome measures were provided. General linear regression models were used to evaluate associations between each exposure and outcome. Univariable analyses were first conducted to estimate the associations of each covariate of interest with each outcome. A multiple regression model was then built to evaluate the adjusted association between each exposure and outcome, including all potential confounders identified with P-value <0.1 from univariable analyses. Child's age at the time of Wechsler assessment, version of the Wechsler assessment, and birth cohort were included in multivariable models as an a-priori decision. For covariates with more than 5% missing data, a missing value indicator was created and included in multivariable models. Covariates with more than 20% missing data (nadir CD4%, peak viral load, PMTCT exposure) were excluded from multivariable analyses. Sensitivity analyses were also conducted which stratified analyses by birth cohort and excluded children with HIV encephalopathy diagnosis.
Analyses were based on the data collected as of 1 October 2012. SAS Version 9.2 (SAS Institute Inc, Cary, North Carolina, USA) was used to conduct all statistical analyses. Two-sided P-values <0.05 were considered statistically significant.
Results
A total of 2210 HIV-infected children from PHACS AMP (n ¼ 225) and PACTG 219C (n ¼ 1985) completed at least one WISC-III or WISC-IV assessment. Of these, 410 children (AMP: 183; 219C: 128; co-enrolled: 99) had at least one viral load measurement either prior to or within 6 months after ART initiation. (Note that viral load measures were not routinely obtained prior to 1998 and were thus more likely unavailable for 219C children.) Fourteen (3%) children with confirmed invalid WISC test results were excluded. As a result, 396 HIV-infected children were included in the analyses (Table 1 ). The mean age at time of WISC evaluation was 9.6 years (IQR 7.3, 11.4); 54% were female, 73% black, 27% Hispanic, and 83% spoke English as their primary language. Overall, 42% of children achieved viral suppression by 5 years of age, with 12% by age 1; 8% between ages 1 and 2; 6% between ages 2 and 3; 8% between ages 3 and 4, and 8% between ages 4 and 5.
There was no difference in FSIQ or composite scores between children who took WISC-IV versus WISC-III tests: FSIQ 86.1 versus 86.7 (P ¼ 0.69), PIQ/PRI 89.7 versus 89.6 (P ¼ 0.94), and VIQ/VCI 86.3 versus 88.5 (P ¼ 0.17). In addition, there was no difference in FSIQ between WISC-III and WISC-IV in the 68 children who were evaluated with both versions. After adjusting for birth cohort, age at the time of WISC evaluation, WISC version, Hispanic ethnicity, primary language of the child, low birth weight, and caregiver's education at study entry, the estimated difference in mean FSIQ (comparing children who were virally suppressed versus unsuppressed) by each age cutoff was 3.7 points at age 1 (P ¼ 0.13), 2.2 at age 2 (P ¼ 0.29), 3.2 at age 3 (P ¼ 0.11), 4.4 at age 4 (P ¼ 0.02), and 3.9 at age 5 (P ¼ 0.03), with higher FSIQ in children who were virally suppressed. After stratifying by birth cohort, viral suppression and higher FSIQ remained associated only in the later birth cohort ( Fig. 1 ) and mean FSIQ was higher in the later birth cohort (data not shown). Restricting the analysis to children without a diagnosis of HIV encephalopathy at study entry did not affect the results (data not shown).
The estimated difference in adjusted mean PIQ/PRI score (comparing children who were virally suppressed versus unsuppressed) by each age cutoff was 3.7 at age 1 (P ¼ 0.13), 2.4 at age 2 (P ¼ 0.25), 2.2 at age 3 (P ¼ 0.27), 4.6 at age 4 (P ¼ 0.01), and 4.5 at age 5 (P ¼ 0.01). After stratifying by birth cohort, viral suppression and higher PIQ/PRI score remained associated only in the later birth cohort (Fig. 2) . No significant associations were found between age of viral suppression and VIQ/VCI. CPE score of initial regimen and weighted-average CPE score were negatively associated with higher FSIQ, PIQ/ PRI, and VIQ/VCI but did not reach statistical significance ( Table 2) . Stratifying by birth cohort and restricting the analysis to children who were virally suppressed did not change the results (data not shown).
Discussion
Our findings demonstrate that early viral suppression is associated with positive impact on cognitive functioning during childhood; children with early viral suppression demonstrated 2.2-4.4 point higher global cognitive scores and 2.2-4.6 point higher perceptual reasoning scores on Wechsler intelligence scales (WISC-III and WISC-IV). Although this association reached statistical significance only for ages 4 and 5, the effect size was consistent across all age groups and our analysis controlled for factors potentially associated with cognitive development during childhood.
In a study nested within a large randomized controlled trial of early versus deferred cART, Laughton et al. [9] found that infants randomized to cART at less than 3 months of age had significantly better short-term neurodevelopmental outcomes at a median age of 11 months compared with those for whom cART was deferred until immunological or clinical progression (median 31.4 weeks). Our study extends this observation by showing that achievement of viral suppression at any age up to 5 years had positive, even though modest, cognitive benefits, as measured by school-age Wechsler scores. However, the number of children who achieved viral suppression at younger than 1 year of age in our study was small (n ¼ 47), and we may not have had sufficient power to detect a difference at this age cutoff. These results are nonetheless encouraging in that children were evaluated at at least 6 years of age when intelligence can be more reliably measured and when the FSIQ is an adequate predictor of school achievement. Although our results did not change after excluding children with a diagnosis of HIV encephalopathy at study entry, it is possible that we missed this diagnosis particularly in the younger than 1 year of age category. This would have biased our results toward the null in the younger age categories as a history of a prior CDC class C diagnosis, in particular HIV encephalopathy, has been shown to be 298 AIDS 2015, Vol 29 No 3 independently associated with later neurocognitive impairment [27] [28] [29] .
Our findings of cognitive benefit of cART are in contrast to those of Puthanakit et al. [11] who examined cognitive outcomes of youth with early and deferred cART after 3 years of follow-up. Children with moderate immunosuppression (CD4 15-24%) and no AIDS-defining illness randomized to early cARTwhen at least 1 year of age did not differ from PHIVþ children for whom cART was deferred until immunological or clinical progression. The median age of their cohort at time of ART initiation was older than our study (6.4 years); thus, very few achieved viral suppression before age 5 [30] , which may have precluded detection of an effect of suppressive cART in early childhood.
It is important to note that although early viral suppression was associated with higher school-age neurocognitive scores in our study, both the suppressed and unsuppressed Fig. 2 . Adjusted Mean Performance Intelligence Quotient/Perceptual Reasoning Index scores by viral suppression at each age cutoff, overall and by birth cohort. Performance Intelligence Quotient from Wechsler Intelligence Scale for Children-III and Perceptual Reasoning Index from Wechsler Intelligence Scale for Children-IV. Children who achieved viral suppression at 4 or less and 5 or less years had significantly higher school-age PIQ/PRI scores compared with children who did not achieve viral suppression by those age cutoffs. Multivariable models were adjusted for birth cohort (in model for overall sample), age at time of WISC evaluation, WISC version, caregiver education level, low birth weight, child's primary language, race, sex, and caregiver identity. PIQ/PRI, Performance IQ/Perceptual Reasoning Index Scores. children scored within the low average/average range of cognitive functioning. In a study conducted by Lowick et al. ART-treated HIV-infected children ages 5-6 had significantly lower general quotient scores by Griffiths Mental Development Scales compared with healthy controls of similar socioeconomic status (mean overall general quotient 70 versus 78, P ¼ 0.001) [31] . The HIVinfected children in their study were virologically suppressed at the time of enrollment; however, the median age of ART initiation was 24 months and 16.67% of their cohort was diagnosed with HIV encephalopathy. These results highlight the fact that some ART-treated HIVinfected children may perform less adequately than their HIV-uninfected peers, particularly if they have a history of AIDS-defining complications. This finding is in keeping with prior studies of cognitive outcomes among youth with HIV and suggests that early CNS effects and/or neuroinflammation that occurs or persists despite effective cART may have subtle or notable negative effects on cognitive development in some children [29] .
We also found that within each age category of viral suppression, mean FSIQ was higher in the later birth cohort. In addition, the association between age of viral suppression and FSIQ was limited to PHIVþ children in the later birth cohort, when use of cART was more common, suggesting that cART may be associated with improved neurocognitive outcomes independent of viral suppression. This is in contrast to prior studies that showed only limited neurodevelopmental improvement after the introduction of protease inhibitor-based cART [32, 33] .
There have been limited studies of the effect of high CNSpenetrating antiretroviral regimens on neurocognitive outcomes in HIV-infected children, and studies in adults have produced conflicting results [14, 16, 17, 20] . Patel et al.
[23] demonstrated a survival benefit and a decrease in HIVencephalopathy incidence in children associated with high CNS-penetrating regimens. In contrast, Shanbhag et al. [22] found no association between number of CNSpenetrating antiretroviral agents and school-aged neurocognitive scores. Although it was suggested that the CPE score represents CNS penetration, the drug levels used for the calculations were derived from the cerebrospinal fluid (CSF) that may not represent levels in the brain parenchyma, the more relevant site for the antiviral effect. Furthermore, published CPE values are based on studies conducted in adults and may not accurately reflect CNS penetration in children. Although studies in adults have shown that higher CPE scoring regimens are associated with viral suppression in the CSF [34] , this has not been confirmed in children due to the difficulties associated with obtaining CSF in children for research purposes. We attempted to address this problem by restricting our analyses to only those with viral suppression in the periphery and did not see a change in our results. It is not surprising that by using a published scoring system for CNS-penetration effectiveness of ART regimens based on adults, we found no association between CPE score of the initial ART regimen and the weighted-average CPE score with FSIQ, PIQ/PRI, or VIQ/VCI. Our findings suggest that CNS-directed cART in early childhood does not have a positive effect on school-age neurocognitive scores. The possibility that the observed nonsignificant negative relationships between CPE and neurocognitive outcomes reflect potential neurotoxicities of high CPE scoring regimens on the developing brain merits further research [35] . 300 AIDS 2015, Vol 29 No 3 Our study has several limitations. The number of children achieving viral suppression prior to 1 year of age was low and may have precluded detection of a difference at this age cutoff. Despite this limitation, the effect size was consistent across all age groups. The two study cohorts included in our analyses were significantly different in many aspects. PACTG 219C was an earlier cohort of children who were diagnosed prior to the availability of cART. Our outcome (WISC-III or WISC-IV) was measured at at least 6 years of age and may have introduced an element of survivor bias as children in PACTG 219C surviving to at least 6 years of age would most likely have been children with less severe disease. We explored the extent of this bias by stratifying analyses by birth cohort (separate analyses for those born prior to and after the wider availability of cART in 1996) and did, in fact, detect the presence of effect modification, such that the association between age at suppression and cognitive function was present only among those born in the later cohort Finally, it is important to note that although the association between age at viral suppression and schoolage neurocognitive scores was statistically significant at ages 4 and 5, the effect sizes are unlikely to be clinically significant.
Conclusion
Virologic suppression during infancy or early childhood is associated with improved school-age neurocognitive outcomes in PHIVþ children. Despite this association, the difference in neurocognitive scores associated with viral suppression is unlikely to be clinically significant and additional interventions to positively impact neurodevelopment in PHIVþ children are needed. CPE scores showed no association with later neurocognitive outcomes. As FSIQ is a composite score that may mask important differences among domains of function, future studies are needed to explore the relationships between virologic suppression and specific neurocognitive domains other than verbal comprehension and perceptual reasoning, including language, executive function, memory, learning and processing speed, especially in perinatally infected youth surviving to adolescence and young adulthood. 
